The CannaWize perspective
Cannabis deserves fair rules—not fear-based policy.
Founded by a former hemp store owner, CannaWize supports adult-only sales, independent testing, honest labels, responsible marketing, and real accountability. We also reject blanket bans and rhetoric that paints responsible hemp businesses, patients, or adult consumers as a threat.
Our reporting covers benefits, evidence-supported medical uses, affordability, access, risks, and uncertainty with the same standard: facts first, stigma never.
Read our full perspective →
Latest Dispatches
See every article →
Texas Smokeable Hemp and Delta-8 Rules: What the July 31 Deadline Really Means
The affected products, the active court fight, and what retailers and consumers should verify now.
CBD Can Help Some People—and It Still Deserves an Informed Approach.
Supported use, emerging benefits, medication interactions, and product quality.
TSA, Airports, and Texas Medical Cannabis: The Federal Line
Why a state prescription does not change federal airport rules.
Goodblend Texas Tea Vape: A Patient-Focused Assessment
Hardware, dose control, effects, limitations, and program context.
Cannabis, Explained
Search all articles →Start with the question you have, not the product someone wants to sell you.
Cannabinoids from THC to CBN
Plain-language chemistry, effects, and product labels.
Patient accessMedical Marijuana by Condition and State
Eligibility, physicians, dispensaries, products, and travel.
EvidenceThe Research Desk
Study methods, effect sizes, uncertainty, and what is not known.
Fact checkMyth Busters
Popular cannabis claims tested against primary sources.
RulesLaw and Policy
Effective dates, agency guidance, court orders, and legislation.
PeopleThe Culture Desk
Music, live events, social rituals, food, language, and changing norms.
MarketsThe Business Desk
Licensing, retail, products, pricing, trademarks, compliance, and sales data.
ProductsIndependent Reviews
Batch records, hardware, value, effects, and disclosure.
Research Desk
All research →We read past the abstract, identify the formulation and population, and separate statistical change from a result people can feel.
Chronic Pain and Cannabinoids: The Final AHRQ Living-Review Update
Twenty-nine randomized trials, patient-to-patient variation, specific benefits, common side effects, and the questions research still needs to answer.
Cannabis and Sleep: Sedation Is Not the Whole Outcome
Product differences, tolerance, withdrawal, next-day function, and why insomnia claims remain unsettled.
Patient resourcePTSD, Eligibility, and the Limits of Current Evidence
Texas access rules alongside a sober account of what clinical research can support.
Foundational guideHow Cannabinoid Claims Move from a Molecule to a Marketing Label
THC, CBD, THCA, CBN, THCV, and the difference between mechanism and proven benefit.
Myth Busters
Check every verdict →“Indica Puts You Down. Sativa Picks You Up.”
Genome-wide research does not find two clean genetic groups behind modern retail labels. Dose, chemistry, route, tolerance, and setting tell you more.
Read the evidence →“CBD Has Benefits and Still Deserves an Informed Approach.”
Non-intoxicating does not mean inactive: supported uses, individual benefits, interactions, side effects, and product quality all matter.
Verdict · Misleading“Texas Gives Patients a Medical Marijuana Card.”
Texas uses a physician-entered CURT prescription, not the conventional wallet-card system.
Medical Cannabis Without the Sales Pitch.
Qualifying conditions, registered physicians, state programs, dispensaries, products, safety, travel, and the questions to ask before paying an evaluation service.
Open the medical hubLocal Guides
All 15 guides →City-level delivery, heat, shipping, state rules, lab reports, and medical access—written for the actual address, not a swapped place name.